Replies to post #45111 on Options Wonderland

[3xBuBu]

Fox cheerfully taking the 70% profit :-)

[3xBuBu]

Vertex (VTRX) has set a new benchmark for the treatment of HCV. Its HCV candidate, Telaprevir, demonstrated significant reduction in viral load with 4.4-log reduction in viral load compared to 1-2 log reduction seen in other standard of care interferon therapy.

We believe that this data sets the bar very high, and we are unsure whether Anadys (ANDS) can reach it. Currently, Telaprevir is undergoing phase III studies. Valeant’s (VRX) Taribavirin (previously known as Viramidine) is in advanced clinical development.

http://www.zacks.com/stock/news/19571/Anadys:+Too+Early+for+HCV+Drug

its counter part ANDS doing poorly